The genetic basis of idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 45, Issue 6, 2015, Pages 1717-1727

  Kropski, Jonathan A ^a   Blackwell, Timothy S ^a,b   Loyd, James E ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSKERIN; NINTEDANIB; PIRFENIDONE; SURFACTANT PROTEIN C; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; DNA HELICASE; MUC5B PROTEIN, HUMAN; MUCIN 5B; RTEL1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SURFACTANT ASSOCIATED PROTEIN; TERT PROTEIN, HUMAN; TOLLIP PROTEIN, HUMAN;

ABCA3 GENE; ARTICLE; CLINICAL FEATURE; DKC1 GENE; ELMOD2 GENE; FIBROSING ALVEOLITIS; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC LINKAGE; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HTR GENE; HUMAN; MOLECULAR MECHANICS; MUC5B GENE; NEXT GENERATION SEQUENCING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RTEL1 GENE; SFTPA2 GENE; SFTPC GENE; SYMPTOMATOLOGY; TELOMERE SHORTENING; TERT GENE; TINF2 GENE; GENETIC PREDISPOSITION; GENETICS; INTERSTITIAL LUNG DISEASE;

DNA HELICASES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG DISEASES, INTERSTITIAL; MUCIN-5B; PULMONARY SURFACTANT-ASSOCIATED PROTEINS; TELOMERASE;

EID: 84930412885     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00163814     Document Type: Article

References (112)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083-2092.
3. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071-2082.
4. Kropski JA, Lawson WE, Young LR, et al. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech 2013; 6: 9-17.
5. Spagnolo P, Grunewald J, du Bois RM. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir Med 2014; 2: 416-428.
6. Bonanni PP, Frymoyer JW, Jacox RF. A family study of idiopathic pulmonary fibrosis. a possible dysproteinemic and genetically determined disease. Am J Med 1965; 39: 411-421.
7. Peabody JW, Peabody JW Jr, Hayes EW, et al. Idiopathic pulmonary fibrosis; its occurrence in identical twin sisters. Dis Chest 1950; 18: 330-344.
8. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338-342.
9. Fernandez BA, Fox G, Bhatia R, et al. A Newfoundland cohort of familial and sporadic idiopathic pulmonary fibrosis patients: clinical and genetic features. Respir Res 2012; 13: 64.
10. Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med 2011; 105: 1902-1907.
11. Loyd JE. Pulmonary fibrosis in families. Am J Respir Cell Mol Biol 2003; 29: Suppl. 3, S47-S50.
12. Coghlan MA, Shifren A, Huang HJ, et al. Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations. BMJ Open Respir Res 2014; 1: e000057.
13. Nogee LM, Dunbar AE 3rd, Wert SE, et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001; 344: 573-579.
14. Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002; 165: 1322-1328.
15. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010; 182: 1419-1425.
16. Ono S, Tanaka T, Ishida M, et al. Surfactant protein C G100S mutation causes familial pulmonary fibrosis in Japanese kindred. Eur Respir J 2011; 38: 861-869.
17. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009; 84: 52-59.
18. Campo I, Zorzetto M, Mariani F, et al. A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res 2014; 15: 43.
19. Epaud R, Delestrain C, Louha M, et al. Combined pulmonary fibrosis and emphysema syndrome associated with ABCA3 mutations. Eur Respir J 2014; 43: 638-641.
20. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007; 356: 1317-1326.
21. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007; 104: 7552-7557.
22. Hisata S, Sakaguchi H, Kanegane H, et al. A novel missense mutation of DKC1 in dyskeratosis congenita with pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2013; 30: 221-225.
23. Kropski JA, Mitchell DB, Markin C, et al. A novel dyskerin (DKC1) mutation is associated with familial interstitial pneumonia. Chest 2014; 146: e1-e7.
24. Alder JK, Parry EM, Yegnasubramanian S, et al. Penetrant telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene. Hum Mutat 2013; 34: 1481-1485.
25. Alder JK, Stanley SE, Wagner CL, et al. Exome sequencing identifies mutant TINF2 in a family with pulmonary fibrosis. Chest 2014 [in press; DOI: 10.1378/chest.14-1947].
26. Fukuhara A, Tanino Y, Ishii T, et al. Pulmonary fibrosis in dyskeratosis congenita with TINF2 gene mutation. Eur Respir J 2013; 42: 1757-1759.
27. Kannengiesser C, Borie R, Revy P. Pulmonary fibrosis associated with TINF2 gene mutation: is somatic reversion required? Eur Respir J 2014; 44: 269-270.
28. Cogan JD, Kropski JA, Zhao M, et al. Rare variants in RTEL1 are associated with familial interstitial pneumonia. Am J Respir Crit Care Med 2015; 191: 646-655.
29. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-alpha gene polymorphisms. Am J Respir Crit Care Med 2000; 162: 755-758.
30. Barlo NP, van Moorsel CH, Korthagen NM, et al. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1beta in idiopathic pulmonary fibrosis. Clin Exp Immunol 2011; 166: 346-351.
31. Korthagen NM, van Moorsel CH, Kazemier KM, et al. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics 2012; 64: 371-377.
32. Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013; 45: 613-620.
33. Ahn MH, Park BL, Lee SH, et al. A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir Res 2011; 12: 73.
34. O'Dwyer DN, Armstrong ME, Trujillo G, et al. The Toll-like receptor 3 L412F polymorphism and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2013; 188: 1442-1450.
35. Mushiroda T, Wattanapokayakit S, Takahashi A, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J Med Genet 2008; 45: 654-656.
36. Korthagen NM, van Moorsel CH, Barlo NP, et al. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. PLoS One 2012; 7: e30442.
37. Xue J, Gochuico BR, Alawad AS, et al. The HLA class II Allele DRB1∗1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One 2011; 6: e14715.
38. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011; 364: 1503-1512.
39. Borie R, Crestani B, Dieude P, et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One 2013; 8: e70621.
40. Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med 2013; 1: 309-317.
41. Peljto AL, Steele MP, Fingerlin TE, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012; 142: 1584-1588.
42. Zhang Y, Noth I, Garcia JG, et al. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N Engl J Med 2011; 364: 1576-1577.
43. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
44. Son JY, Kim SY, Cho SH, et al. TGF-beta1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity. Lung 2013; 191: 199-205.
45. Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003; 168: 431-435.
46. Horimasu Y, Ohshimo S, Bonella F, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: 439-444.
47. Stock CJ, Sato H, Fonseca C, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 2013; 68: 436-441.
48. Peljto AL, Selman M, Kim DS, et al. The MUC5B promoter polymorphism is associated with IPF in a Mexican cohort but is rare among Asian ancestries. Chest 2015; 147: 460-464.
49. Wei R, Li C, Zhang M, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. Transl Res 2014; 163: 494-502.
50. Seibold MA, Smith RW, Urbanek C, et al. The idiopathic pulmonary fibrosis honeycomb cyst contains a mucocilary pseudostratified epithelium. PLoS One 2013; 8: e58658.
51. Hunninghake GM, Hatabu H, Okajima Y, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med 2013; 368: 2192-2200.
52. Roy MG, Livraghi-Butrico A, Fletcher AA, et al. Muc5b is required for airway defence. Nature 2014; 505: 412-416.
53. Steele MP, Speer MC, Loyd JE, et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005; 172: 1146-1152.
54. Scholand MB, Coon H, Wolff R, et al. Use of a genealogical database demonstrates heritability of pulmonary fibrosis. Lung 2013; 191: 475-481.
55. Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res 2012; 730: 52-58.
56. Calado RT, Young NS. Telomere diseases. N Engl J Med 2009; 361: 2353-2365.
57. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 2008; 105: 13051-13056.
58. Cronkhite JT, Xing C, Raghu G, et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 729-737.
59. Uringa EJ, Lisaingo K, Pickett HA, et al. RTEL1 contributes to DNA replication and repair and telomere maintenance. Mol Biol Cell 2012; 23: 2782-2792.
60. Vannier JB, Sandhu S, Petalcorin MI, et al. RTEL1 is a replisome-associated helicase that promotes telomere and genome-wide replication. Science 2013; 342: 239-242.
61. Vannier JB, Sarek G, Boulton SJ. RTEL1: functions of a disease-associated helicase. Trends Cell Biol 2014; 24: 416-425.
62. Masutomi K, Possemato R, Wong JM, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci USA 2005; 102: 8222-8227.
63. Kropski JA, Pritchett JM, Zoz DF, et al. Extensive phenotyping of individuals at-risk for familial interstitial pneumonia reveals clues to the pathogenesis of interstitial lung disease. Am J Respir Crit Care Med 2015; 191: 417-427.
64. Diaz de Leon A, Cronkhite JT, Katzenstein AL, et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010; 5: e10680.
65. Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014; 2: 557-565.
66. Theall KP, McKasson S, Mabile E, et al. Early hits and long-term consequences: tracking the lasting impact of prenatal smoke exposure on telomere length in children. Am J Public Health 2013; 103: Suppl. 1, S133-S135.
67. Driscoll B, Buckley S, Bui KC, et al. Telomerase in alveolar epithelial development and repair. Am J Physiol Lung Cell Mol Physiol 2000; 279: L1191-L1198.
68. Lee J, Reddy R, Barsky L, et al. Lung alveolar integrity is compromised by telomere shortening in telomerase-null mice. Am J Physiol Lung Cell Mol Physiol 2009; 296: L57-L70.
69. Alder JK, Guo N, Kembou F, et al. Telomere length is a determinant of emphysema susceptibility. Am J Respir Crit Care Med 2011; 184: 904-912.
70. Degryse AL, Xu XC, Newman JL, et al. Telomerase deficiency does not alter bleomycin-induced fibrosis in mice. Exp Lung Res 2012; 38: 124-134.
71. Liu T, Chung MJ, Ullenbruch M, et al. Telomerase activity is required for bleomycin-induced pulmonary fibrosis in mice. J Clin Invest 2007; 117: 3800-3809.
72. Cottin V, Reix P, Khouatra C, et al. Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. Thorax 2011; 66: 918-919.
73. Tanjore H, Blackwell TS, Lawson WE. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012; 302: L721-L729.
74. Bridges JP, Wert SE, Nogee LM, et al. Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice. J Biol Chem 2003; 278: 52739-52746.
75. Lawson WE, Crossno PF, Polosukhin VV, et al. Endoplasmic reticulum stress in alveolar epithelial cells is prominent in IPF: association with altered surfactant protein processing and herpesvirus infection. Am J Physiol Lung Cell Mol Physiol 2008; 294: L1119-L1126.
76. Mulugeta S, Maguire JA, Newitt JL, et al. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol 2007; 293: L720-L729.
77. Mulugeta S, Nguyen V, Russo SJ, et al. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 2005; 32: 521-530.
78. Wang WJ, Mulugeta S, Russo SJ, et al. Deletion of exon 4 from human surfactant protein C results in aggresome formation and generation of a dominant negative. J Cell Sci 2003; 116: 683-692.
79. Beers MF, Hawkins A, Maguire JA, et al. A nonaggregating surfactant protein C mutant is misdirected to early endosomes and disrupts phospholipid recycling. Traffic 2011; 12: 1196-1210.
80. Hawkins A, Guttentag SH, Deterding R, et al. A non-BRICHOS SFTPC mutant (SP-CI73 T) linked to interstitial lung disease promotes a late block in macroautophagy disrupting cellular proteostasis and mitophagy. Am J Physiol Lung Cell Mol Physiol 2015; 308: L33-L47.
81. Lawson WE, Cheng DS, Degryse AL, et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci USA 2011; 108: 10562-10567.
82. Maguire JA, Mulugeta S, Beers MF. Multiple ways to die: delineation of the unfolded protein response and apoptosis induced by Surfactant Protein C BRICHOS mutants. Int J Biochem Cell Biol 2012; 44: 101-112.
83. Maguire JA, Mulugeta S, Beers MF. Endoplasmic reticulum stress induced by surfactant protein C BRICHOS mutants promotes proinflammatory signaling by epithelial cells. Am J Respir Cell Mol Biol 2011; 44: 404-414.
84. Tanjore H, Cheng DS, Degryse AL, et al. Alveolar epithelial cells undergo epithelial-to-mesenchymal transition in response to endoplasmic reticulum stress. J Biol Chem 2011; 286: 30972-30980.
85. Maitra M, Dey M, Yuan WC, et al. Lung fibrosis-associated surfactant protein A1 and C variants induce latent transforming growth factor beta1 secretion in lung epithelial cells. J Biol Chem 2013; 288: 27159-27171.
86. Maitra M, Wang Y, Gerard RD, et al. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem 2010; 285: 22103-22113.
87. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004; 59: 977-980.
88. Markart P, Ruppert C, Wygrecka M, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J 2007; 29: 134-137.
89. Korfei M, Ruppert C, Mahavadi P, et al. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 178: 838-846.
90. Isler JA, Skalet AH, Alwine JC. Human cytomegalovirus infection activates and regulates the unfolded protein response. J Virol 2005; 79: 6890-6899.
91. Geraghty P, Wallace A, D'Armiento JM. Induction of the unfolded protein response by cigarette smoke is primarily an activating transcription factor 4-C/EBP homologous protein mediated process. Int J Chron Obstruct Pulmon Dis 2011; 6: 309-319.
92. Hengstermann A, Muller T. Endoplasmic reticulum stress induced by aqueous extracts of cigarette smoke in 3T3 cells activates the unfolded-protein-response-dependent PERK pathway of cell survival. Free Radic Biol Med 2008; 44: 1097-1107.
93. Zhao H, Yang J, Shan L, et al. Measuring the impact of cigarette smoke on the UPR. Methods Enzymol 2011; 489: 147-164.
94. Stewart GA, Ridsdale R, Martin EP, et al. 4-Phenylbutyric acid treatment rescues trafficking and processing of a mutant surfactant protein-C. Am J Respir Cell Mol Biol 2012; 47: 324-331.
95. Crossno PF, Polosukhin VV, Blackwell TS, et al. Identification of early interstitial lung disease in an individual with genetic variations in ABCA3 and SFTPC. Chest 2010; 137: 969-973.
96. Hodgson U, Pulkkinen V, Dixon M, et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am J Hum Genet 2006; 79: 149-154.
97. Pulkkinen V, Bruce S, Rintahaka J, et al. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J 2010; 24: 1167-1177.
98. Bamshad MJ, Ng SB, Bigham AW, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011; 12: 745-755.
99. Futema M, Plagnol V, Li K, et al. Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations. J Med Genet 2014; 51: 537-544.
100. Renton AE, Chio A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 2014; 17: 17-23.
101. Hershberger RE, Hedges DJ, Morales A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat Rev Cardiol 2013; 10: 531-547.
102. Esteban-Jurado C, Vila-Casadesus M, Garre P, et al. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer. Genet Med 2015; 17: 131-142.
103. Hu H, Roach JC, Coon H, et al. A unified test of linkage analysis and rare-variant association for analysis of pedigree sequence data. Nat Biotechnol 2014; 32: 663-669.
104. Novarino G, Fenstermaker AG, Zaki MS, et al. Exome sequencing links corticospinal motor neuron disease to common neurodegenerative disorders. Science 2014; 343: 506-511.
105. Silhan LL, Shah PD, Chambers DC, et al. Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. Eur Respir J 2014; 44: 178-187.
106. Etchegary H, Pullman D, Simmonds C, et al. 'It had to be done': genetic testing decisions for arrhythmogenic right ventricular cardiomyopathy. Clin Genet 2014 [in press; DOI: 10.1111/cge.12513].
107. Schuurman AG, van der Kolk DM, Verkerk MA, et al. Maximising the efficiency of clinical screening programmes: balancing predictive genetic testing with a right not to know. Eur J Hum Genet 2015 [in press; DOI: 10.1038/ejhg.2014.269].
108. Chio A, Battistini S, Calvo A, et al. Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014; 85: 478-485.
109. Ghaedi M, Calle EA, Mendez JJ, et al. Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. J Clin Invest 2013; 123: 4950-4962.
110. Yan Q, Quan Y, Sun H, et al. A site-specific genetic modification for induction of pluripotency and subsequent isolation of derived lung alveolar epithelial type II cells. Stem Cells 2014; 32: 402-413.
111. Cho SW, Kim S, Kim JM, et al. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol 2013; 31: 230-232.
112. Wang H, Yang H, Shivalila CS, et al. One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering. Cell 2013; 153: 910-918.